Cobblestone Capital Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Cobblestone Capital Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,000	Closed	-$242K	–	286
2024 Q1	$242K	Hold	9,000	–	–	0.02%	247
2023 Q4	$270K	Buy	+9,000	New	+$199K	0.02%	236
2021 Q4	–	Sell	-9,000	Closed	-$269K	–	264
2021 Q3	$269K	Sell	9,000 -9,000	-50%	-$328K	0.02%	223
2021 Q2	$797K	Hold	18,000	–	–	0.05%	134
2021 Q1	$799K	Hold	18,000	–	–	0.06%	129
2020 Q4	$987K	Hold	18,000	–	–	0.08%	112
2020 Q3	$411K	Hold	18,000	–	–	0.04%	168
2020 Q2	$377K	Hold	18,000	–	–	0.03%	180
2020 Q1	$251K	Hold	18,000	–	–	0.03%	215
2019 Q4	$410K	Hold	18,000	–	–	0.04%	187
2019 Q3	$210K	Hold	18,000	–	–	0.02%	229
2019 Q2	$270K	Hold	18,000	–	–	0.02%	208
2019 Q1	$316K	Hold	18,000	–	–	0.03%	192
2018 Q4	$267K	Hold	18,000	–	–	0.03%	198
2018 Q3	$443K	Hold	18,000	–	–	0.04%	164
2018 Q2	$353K	Buy	+18,000	New	+$341K	0.03%	180

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cobblestone Capital Advisors's RCKT Position: Q2 2024 in Review

Cobblestone Capital Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2024, closing a stake of 9,000 shares — an estimated $242K sold.

Cobblestone Capital Advisors first reported a position in RCKT in Q2 2018 and held it in 16 quarters. The position peaked at $987K in Q4 2020. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2024.

Cobblestone Capital Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Cobblestone Capital Advisors sold 9,000 Rocket Pharmaceuticals shares in Q2 2024, an estimated $242K.
Cobblestone Capital Advisors first reported a position in Rocket Pharmaceuticals in Q2 2018 and held it in 16 quarters.
Cobblestone Capital Advisors's Rocket Pharmaceuticals position peaked at $987K in Q4 2020.
178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2024.

Based on Cobblestone Capital Advisors's 13F filing for Q2 2024, filed 6 Aug 2024.